Surface analysis exposes counterfeit medicines
Scientists have discovered a new way for bacteria to transfer toxic genes to unrelated bacterial species, a finding that raises the unsettling possibility that bacterial swapping of toxins and other disease-aiding factors may be more common than previously imagined. In a laboratory experiment, the scientists from NYU School of Medicine discovered that Staphylococcus aureus, a
Full Post: Discovery of new way for bacteria to transfer toxic genes to unrelated bacterial species
CERAM Surface and Materials Analysis has published a white paper highlighting how surface analysis can expose counterfeit medicines. It describes how technologies such as X-ray photoelectron spectroscopy (XPS) and Time-of-Flight Secondary Ion Mass Spectroscopy (ToFSIMS) are being used in novel ways to not only analyse the composition of various pharmaceuticals, but also to determine differences in the manufacturing processes involved.
The author of the white paper, Dr. Justine Bentley, explains how technology is helping to stem the trade in counterfeit drugs. She says:
“Counterfeit medicines are incredibly dangerous and represent a significant challenge to public health, so it is vital that drug manufacturers and authorities implement stringent QA processes. Surface analysis enables the identification of previously undetectable chemical copies and the technology is now so sophisticated that we can determine the manufacturing process of, for example, a particular tablet to find out if it has been produced by the correct licensed process. If it hasn’t, then that tablet is as much a potential health hazard as one that contains the wrong ingredient.”
According to the World Health Organization, counterfeit medicines are part of the broader substandard pharmaceuticals sector - medicines manufactured below established quality standards and, therefore, dangerous to patients’ health and ineffective for the treatment of diseases. They are deliberately and fraudulently mislabelled with respect to identity or source. The US-based Centre for Medicines in the Public Interest predicts that counterfeit drug sales will be worth an estimated US$75 billion globally in 2010, a staggering increase of more than 90% from 2005.
With more than twenty five years’ experience, CERAM Surface and Materials Analysis is Europe’s leading surface and materials analysis company, specialising in both the chemical and physical characterisation of surfaces. It remains at the forefront of research into fake drugs, while continuing to assist the pharmaceutical industry with product development and quality assessment as well as contamination identification and evaluation of packaging stability.
The white paper is available as a free download at: www.csma.ltd.uk/pharmaceutical/counterfeit-drugs.htm
Codexis, Inc. today announced a licensing agreement with Teva Pharmaceutical Industries Ltd., to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst. Teva, the largest generic drug manufacturer in the world, is a leading producer of this generic product. The product is one of the largest- selling generic prescription drugs in the United
Full Post: Codexis announces licensing agreement with Teva Pharmaceutical Industries
Research chemists at the University of Warwick have devised an elegant process which simply and cheaply covers small particles of polymer with a layer of silica-based nanoparticles. The final result provides a highly versatile material that can be used to create a range of high performance materials such as: self healing paints, and clever packaging
Full Post: Scientists create new soap free emulsion polymerization process
You will be familiar from many diseases in this world but some of these diseases are very dangerous. Some diseases can become the cause of death so you should treat this problem. Some diseases can be treated by the use of simple medicines. You know that cough and flu have become the common health
Full Post: Erectile dysfunction Vs Blood flow
Scientists at the University of Liverpool have developed a new technology which can dramatically improve the effectiveness of antibacterial treatments. Drugs with the ability to dissolve have much stronger efficacy, however many drugs are insoluble. In order to compensate, drugs often need to be administered in higher doses. This increases the possibility of bacteria and
Full Post: Nanoparticles dramatically improve effectiveness of antibacterial treatments
Roche and Memory Pharmaceuticals has announced that the two companies have signed a definitive merger agreement for Roche to acquire all the outstanding shares of Memory Pharmaceuticals in an all-cash transaction for an aggregate price of approximately USD 50 million. Memory Pharmaceuticals develops innovative drug candidates for the treatment of debilitating central nervous system (CNS)
Full Post: Roche to acquire Memory Pharmaceuticals